Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.61 |
| ▸ | GLP1R | P43220 | 5/20 | 0.57 |
| ▸ | ECE1 | P42892 | 1/20 | 0.57 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.57 |
| ▸ | VIPR1 | P32241 | 2/20 | 0.56 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.54 |
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.53 |
| ▸ | VIPR2 | P41587 | 2/20 | 0.53 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16015184 | 1.00 | TFPI (0.61) | TFPIGLP1RECE1MUS81VIPR1 | |
| SCHEMBL2881677 | 1.00 | TFPI (0.61) | TFPIGLP1RECE1MUS81VIPR1 | |
| SCHEMBL13324659 | 1.00 | TFPI (0.61) | TFPIGLP1RECE1MUS81VIPR1 | |
| SCHEMBL12359225 | 1.00 | TFPI (0.61) | TFPIGLP1RECE1MUS81VIPR1 | |
| SCHEMBL13342836 | 1.00 | TFPI (0.61) | TFPIGLP1RECE1MUS81VIPR1 | |
| SCHEMBL13912288 | 1.00 | TFPI (0.61) | TFPIGLP1RECE1MUS81VIPR1 | |
| SCHEMBL15629783 | 0.98 | TFPI (0.60) | TFPIGLP1RECE1MUS81VIPR1 | |
| SCHEMBL16329662 | 0.97 | TFPI (0.61) | TFPIGLP1RECE1MUS81VIPR1 | |
| SCHEMBL13906498 | 0.96 | TFPI (0.58) | TFPIGLP1RECE1MUS81VIPR1 | |
| SCHEMBL29470903 | 0.96 | TFPI (0.64) | TFPIGLP1RECE1MUS81VIPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933024-B2 | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases | SANOFI (FR) | 2015-01-13 | — | — | US | disclosed |
| US-8895547-B2 | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof | SANOFI (FR) | 2014-11-25 | — | — | US | disclosed |
| US-20130157941-A1 | AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI (FR) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130157941-A1 | AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | PNLIP, LPL, CEL | TFPI 1022/4885GLP1R 729/4885ECE1 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.